This is an open-label phase II study of venetoclax in combination with obinutuzumab and bendamustine. Patients will receive induction therapy with venetoclax, obinutuzumab and bendamustine for six cycles (1 cycle = 28 days). There will be a formal, detailed toxicity evaluation after 28 patients complete 3 cycles of treatment.